On the questions around glufosinate, which I used in my example, in that example, the U.S. has access to use a new form of glufosinate that, unfortunately, we don't have access to in Canada because glufosinate's going through special review. The special review process works such that we can't submit any label changes or new chemistries associated with glufosinate during that special review.
I'm not sure if that answers your question, but that also has an impact as it relates to InVigor as well.